Prof Ed Gane
Auckland, New Zealand
NCT Number: NCT00781976
PK, safety study of AZD7295 in HCV carriers
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Auckland, New Zealand
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
700mg per day maximum
matched placebo
Time frame: 5 days
Looking for future studies?
Notify MeArrow Therapeutics
Industry
A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00004850
Blood-Borne Infections, Communicable Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04961723
Behavior, Blood-Borne Infections
Batumi, Georgia
View Trial DetailsNCT04971538
Blood-Borne Infections, Communicable Diseases
Karachi, Sindh, Pakistan
View Trial DetailsNCT04982718
Blood-Borne Infections, Communicable Diseases
Alor Star, Kedah, Malaysia
View Trial Details